Fundraising Fox
/Companies
Sign in

ChromaCode

Carlsbad, US · Founded 2012 · Delaware corporation · 18 employees on LinkedIn · 9 known investors

Find your way into ChromaCode

Sign up to see every warm intro you have to ChromaCode

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the ChromaCode team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

ChromaCode develops a High-Definition PCR (HDPCR) multiplexing platform that enables genomic solutions for oncology and precision medicine, offering faster results and cost-effective workflows through automated interpretation and cloud-based software.

AI & Machine LearningBiotechHealthtechMedical Devices

Founders & leadership

PFPaul Flook
Paul FlookPresident and CEOPaul Flook earned a PhD in molecular genetics and spent over a decade developing molecular diagnostic platforms combining chemistry, computation, and cloud infrastructure. Before becoming CEO of ChromaCode in March 2024, he held Chief R&D Officer, Chief Information Officer, and VP of Software Engineering roles at the company, and previously led scientific software platform development at Illumina and BIOVIA.
GJ
Gregory J. GoschExecutive
LR
Lynne RollinsExecutive
AR
Aditya RajagopalFounder & Independant Board DirectorVenture Partner at +ND Capital
AS
Axel SchererNamed on SEC filing

Board

JKJustin Klein
Justin KleinBoard directorCo-Founder and Managing Partner at Vensana Capital
JC
James C. BlairBoard directorPartner at Domain Associates
AG
Alexander G. DickinsonBoard director

Investors · 9

Global Brainlisted by Global BrainTokyo · $100K

How we know: Global Brain's portfolio page · press coverage · open dataset · 5k.vc investor directory · Not right? Tell us

Moore Venture Partnerslisted by Moore Venture PartnersSan Diego

How we know: Moore Venture Partners's portfolio page · Not right? Tell us

New Enterprise Associates (NEA)listed by New Enterprise Associates (NEA)Menlo Park · $200K – $40M

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

Windham Capital Partnerslisted by Windham Capital PartnersNew York · $1M – $5M
Domain AssociatesreportedPrinceton · $200K – $15M

How we know: a partner's Signal profile · funding news · open dataset · 5k.vc investor directory · Not right? Tell us

Domain PartnersinferredPrinceton

How we know: board seat on SEC Form D · Not right? Tell us

Northpond VenturesreportedBethesda · $100K – $5M

How we know: funding news · Not right? Tell us

Vensana CapitalreportedMinneapolisvia Justin Klein · board

How we know: board seat on SEC Form D · the VCSheet dataset · Not right? Tell us

Funding

SEC filings, press & company announcements

$94.2M disclosed across 5 of 7 rounds · 2017–2025

▶$3.8MraisedFeb 2025 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Aditya RajagopalDirector
  • Paul FlookExecutive Officer, Director
  • Justin KleinDirector
Offering amount
$5M
Amount sold
$3.8M
First sale
Jan 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$38MraisedFeb 2023 · 16 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark McDonoughExecutive Officer, Director
  • Justin KleinDirector
  • Pat SmerkersDirector
  • Alexander G. DickinsonDirector
  • Kevin O'BoyleDirector
  • Carol GallagherDirector
  • Aditya RajagopalDirector
  • Jenny YipDirector
Offering amount
$43M
Amount sold
$38M
First sale
Feb 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$38.6MraisedDec 2020 · 17 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jenny YipDirector
  • Lynne RollinsExecutive Officer
  • Pat SmerkersDirector
  • Carol GallagherDirector
  • James C. BlairDirector
  • Alexander G. DickinsonDirector
  • Aditya RajagopalDirector
  • Gregory J. GoschExecutive Officer, Director
Offering amount
$41.2M
Amount sold
$38.6M
First sale
Aug 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.8MraisedApr 2019 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • James C. BlairDirector
  • Carol GallagherDirector
  • Alexander G. DickinsonDirector
  • Gregory J. GoschExecutive Officer, Director
  • Aditya RajagopalDirector
  • Lynne RollinsExecutive Officer
Offering amount
$3.5M
Amount sold
$1.8M
First sale
Apr 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$12MraisedApr 2017 · 9 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • James C. BlairDirector
  • Gregory J. GoschExecutive Officer, Director
  • Peter Justin KleinDirector
  • Axel SchererDirector
  • Alexander G. DickinsonDirector
  • Lynne RollinsExecutive Officer
Offering amount
$12.1M
Amount sold
$12M
First sale
Apr 2017
Incorporated
Corporation, Delaware, 2012
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through ChromaCode went on to found or lead other companies.

Ryan DittamoreIndependent DirectorFounded Tensorbio +1Aditya RajagopalDirectorFounded Esperto Medical

Related companies · 2

Transcode TherapeuticsTransCode Therapeutics is an RNA-focused drug developer building oncology therapeutic candidates and diagnostics, using its TTX delivery technology across immunotherapy, gene editing, radiotherapy, and cancer vaccines. Its pipeline targets cancers such as pancreatic cancer through RNAi, RIG-I agonism, CRISPR, radioisotope delivery, and mRNA-based vaccines.
JUMPCODE GenomicsJumpcode Genomics develops CRISPRclean, a next-generation sequencing technology that removes abundant, uninformative sequences to improve sensitivity, lower costs, and simplify workflows for researchers. Its technology is used in basic research, infectious disease, oncology, and consumer genomics.

Companies working in the same space as ChromaCode.

In the news

ChromaCode Announces Strategic Investment to Advance Development and Application of HDPCR Platform Technology for Use in Oncology Genomicsprnewswire.com · Jun 2023ChromaCode Raises $10 Million Series C Financing From Adjuvant Capitalprnewswire.com · May 2020

Frequently asked questions

What does ChromaCode do?
ChromaCode develops a High-Definition PCR (HDPCR) multiplexing platform that enables genomic solutions for oncology and precision medicine, offering faster results and cost-effective workflows through automated interpretation and cloud-based software.
Who are ChromaCode's investors?
ChromaCode's investors include Adjuvant Capital, Global Brain, Moore Venture Partners, New Enterprise Associates (NEA), Windham Capital Partners, Domain Associates, Domain Partners, Northpond Ventures and 1 more.
How much funding has ChromaCode raised?
ChromaCode has disclosed $94.2M raised across 5 of its 7 known rounds.
Where is ChromaCode headquartered?
ChromaCode is headquartered in Carlsbad, US.